Please assess the completion status of the following clinical trial:

Trial Title: Heart Outcomes Prevention Evaluation-3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged \> 60 years and men \> 55 years~* At least one additional CV risk factor including:~* Waist/hip ratio ≥ 0.90 in men and ≥ 0.85 in women;~* History of current or recent smoking (regular tobacco use within 5 years)~* Low HDL cholesterol~* Dysglycemia~* Renal dysfunction~* Family history of premature CHD in first degree relatives~Exclusion Criteria:~* Documented clinically manifest atherothrombotic CVD~* Clear indication or contraindication for statin and/or ARB or ACE inhibitor and/or thiazide diuretic therapy~* Symptomatic hypotension~* Chronic liver disease~* Inflammatory muscle disease~* Renal impairment~* Concurrent treatment with cyclosporine or a condition likely to result in organ transplantation and the need for cyclosporine~* Concurrent treatment with a statin, fibrate, angiotensin receptor blocker, ACE inhibitor, or a thiazide diuretic~* Other serious medical illness likely to interfere with study participation or with the ability to complete the trial~* Significant psychiatric illness, senility, dementia, alcohol or substance abuse, which could impair the ability to provide informed consent and to adhere to the trial procedures~* Concurrent use of an experimental pharmacological agent

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Rosuvastatin (Type: PLACEBO_COMPARATOR): Rosuvastatin 10 mg vs placebo
- Candesartan/HCT (Type: PLACEBO_COMPARATOR): Candesartan 16 mg/HCT 12.5 mg vs placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).